Live preview mode. Wire is not yet published.
Macquarie says Mesoblast's MSB's acquisition of Osiris's cultured stem-cell assets is a worrying sign for the industry
Macquarie says Mesoblast's MSB's acquisition of Osiris's cultured stem-cell assets is a worrying sign for the industry. Whilst this transaction appears to offer little downside for MSB, they are concerned that a insider and pioneer is seemingly giving up on the industry. The low transaction price suggests both a low internal value placed on stem-cell therapies, and little interest from external parties.
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Tom McKay is the Co-Founder and Managing Director of Livewire. Tom's passionate about democratising access to high quality investment ideas and insights, so all investors can make more informed and successful investment decisions.
1 topic
Comments
Comments
Sign In or Join Free to comment